• 1
    Bernatsky S, Clarke A, Ramsey-Goldman R. Malignancy and systemic lupus erythematosus. Curr Rheumatol Rep 2002; 4: 3518.
  • 2
    Oertel SH, Riess H. Immunosurveillance, immunodeficiency and lymphoproliferation. Recent Results Cancer Res 2002; 159: 18.
  • 3
    Boubenider S, Hiesse C, Goupy C, Kriaa F, Marchand S, Charpentier B. Incidence and consequences of post-transplantation lymphoproliferative disorders. J Nephrol 1997; 10: 13645.
  • 4
    Ehrenfeld M, Abu-Shakra M, Buskila D, Shoenfeld Y. The dual association between lymphoma and autoimmunity. Blood Cells Mol Dis 2001; 27: 7506.
  • 5
    Mariette X. Lymphomas in patients with Sjogren's syndrome: review of the literature and physiopathologic hypothesis. Leuk Lymphoma 1999; 33: 939.
  • 6
    Bernatsky S, Boivin JF, Joseph L, St Pierre Y, Rajan R, Clarke AE. The prevalence of factors influencing cancer risk in women with lupus: social habits, reproductive issues and obesity. J Rheumatol 2002; 29: 25514.
  • 7
    Abu-Shakra M, Gladman DD, Urowitz MB. Malignancy in systemic lupus erythematosus. Arthritis Rheum 1996; 39: 10504.
  • 8
    Bjornadal L, Lofstrom B, Yin L, Lundberg I, Ekbom A. Increased cancer incidence in a Swedish cohort of patients with systemic lupus erythematosus. Scand J Rheumatol 2002; 31: 6671.
  • 9
    Cibere J, Sibley J, Haga M. Systemic lupus erythematosus and the risk of malignancy. Lupus 2001; 10: 394400.
  • 10
    Mellemkjaer L, Andersen V, Linet MS, Gridley G, Hoover R, Olsen JH. Non-Hodgkin's lymphoma and other cancers among a cohort of patients with systemic lupus erythematosus. Arthritis Rheum 1997; 40: 7618.
  • 11
    Nived O, Bengtsson A, Jonsen A, Sturfelt G, Olsson H. Malignancies during follow-up in an epidemiologically defined SLE inception cohort in southern Sweden. Lupus 2001; 10: 5004.
  • 12
    Pettersson T, Pukkala E, Teppo L, Friman C. Increased risk of cancer in patients with systemic lupus erythematosus. Ann Rheum Dis 1992; 51: 4379.
  • 13
    Ramsey-Goldman R, Mattai SA, Schilling E, Chiu YL, Alo CJ, Howe HL. Increased risk of malignancy in patients with systemic lupus erythematosus. J Investig Med 1998; 46: 21722.
  • 14
    Sultan SM, Ioannou Y, Isenberg DA. Is there an association of malignancy with systemic lupus erythematosus? An analysis of 276 patients under long-term review. Rheumatology (Oxford) 2000; 39: 114752.
  • 15
    Sweeney DM, Manzi S, Janosky J, Selvaggi K, Ferri W, Medsger TA, et al. Risk of malignancy in women with SLE. J Rheumatol 1995; 22: 147882.
  • 16
    Hughes G. Lupus patients are protected from cancer. Lupus 2002; 10: 8334.
  • 17
    Isenberg DA, Gladman DD. The Systemic Lupus International Collaborating Clinics Group: origins and outcomes. Lupus 2001; 10: 3757.
  • 18
    Hochberg MC, for the Diagnostic and Therapeutic Criteria Committee of the American College of Rheumatology. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [letter]. Arthritis Rheum 1997; 40: 1725.
  • 19
    Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 12717.
  • 20
    Breslow NE, Day NE. Statistical methods in cancer research: the design and analysis of cohort studies. Lyon: WHO International Agency for Research on Cancer; 1987. p. 3024.
  • 21
    Gelman A, Carlin J, Stern H, Rubin H. Bayesian data analysis. New York: Chapman and Hall; 1995.
  • 22
    George E, Makov I, Smith A. Conjugate likelihood distributions. Scand J Stat 1993; 20: 14756.
  • 23
    Wells C, Peduzzi P, Feinstein A. Presenting manifestations, cigarette smoking, and detection bias in age at diagnosis of lung cancer. Ann Epidemiol 2001; 11: 23947.
  • 24
    Walker A. Observation and inference: an introduction to the methods of epidemiology. Newton Lower Falls (MA): Epidemiology Resources Inc; 1991.
  • 25
    Urowitz MB, Albanez D, and all SLICC members. Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort Registry to study risk factors for atherosclerosis: initial report [abstract]. Arthritis Rheum 2004; 50 Suppl 9: S5945.
  • 26
    Pangalis G, Angelopoulou M, Vassilakopoulos T, Siakantaris M, Kittas C. B-chronic lymphocytic leukemia, small lymphocytic lymphoma, and lymphoplasmacytic lymphoma, including Waldenstrom's macroglobulinemia: a clinical, morphologic, and biologic spectrum of similar disorders. Semin Hematol 1999; 36: 10414.
  • 27
    Bezwoda W, Dansey R. Aggressive non-Hodgkin's lymphoma: long-term results of full dose CHOP chemotherapy, and analysis of prognostic determinant. Leuk Lymphoma 2004; 20: 30310.
  • 28
    Bernatsky S, Clarke A, Ramsey-Goldman R, Boivin JF, Joseph L, Rajan R, et al. Breast cancer stage at time of detection in women with systemic lupus erythematosus (SLE). Lupus 2004; 13: 46972.
  • 29
    MacLean CH, Louie R, Leake B, McCaffrey DF, Paulus HE, Brook RH, et al. Quality of care for patients with rheumatoid arthritis. JAMA 2000; 284: 98492.
  • 30
    Moss KE, Ioannou Y, Sultan SM, Haq I, Isenberg DA. Outcome of a cohort of 300 patients with systemic lupus erythematosus attending a dedicated clinic for over two decades. Ann Rheum Dis 2002; 61: 40913.
  • 31
    Yoshitomo H, Sachiko H, Akinori I, Masaaki A, Danqing Z, Sanki K, et al. Susceptibility alleles for aberrant B-1 cell proliferation involved in spontaneously occurring B-cell chronic lymphocytic leukemia in a model of New Zealand white mice. Blood 1998; 92: 37729.
  • 32
    Straus SE, Jaffe ES, Puck JM, Dale JK, Elkon KB, Rosen-Wolff A, et al. The development of lymphomas in families with autoimmune lymphoproliferative syndrome with germline Fas mutations and defective lymphocyte apoptosis. Blood 2001; 98: 194200.
  • 33
    Schultz DR, Harrington WJ Jr. Apoptosis: programmed cell death at a molecular level [review]. Semin Arthritis Rheum 2003; 32: 34569.
  • 34
    Bernatsky S, Clarke A, Rajan R, Boivin JF, Joseph L, Lachance S, et al. Non-Hodgkin's lymphoma in systemic lupus erythematosus [abstract]. Arthritis Rheum 2004; 50 Suppl 9: S691.
  • 35
    Baecklund E, Sundstrom C, Ekbom A, Catrina AT, Biberfeld P, Feltelius N, et al. Lymphoma subtypes in patients with rheumatoid arthritis: increased proportion of diffuse large B cell lymphoma. Arthritis Rheum 2003; 48: 154350.
  • 36
    Freedman A, Nadler L. Non-Hodgkin's lymphomas. In: BastR, KufeW, PollockR, WeichselbaumR, HollandJ, et al, editors. Cancer medicine. Hamilton (Canada): BC Decker Inc; 2000.
  • 37
    Hehir ME, Sewell JR, Hughes GR. Reticulum cell sarcoma in azathioprine-treated systemic lupus erythematosus. Ann Rheum Dis 1979; 38: 945.
  • 38
    Cras P, Franckx C, Martin J. Primary intracerebral lymphoma in systemic lupus erythematosus treated with immunosuppressives. Clin Neuropathol 1989; 8: 2005.
  • 39
    Ortiz AM, Gonzalez-Parra E, Alvarez-Costa G, Egido J. Bladder cancer after cyclophosphamide therapy for lupus nephritis. Nephron 1992; 60: 3789.
  • 40
    Elliott RW, Essenhigh DM, Morley AR. Cyclophosphamide treatment of systemic lupus erythematous: risk of bladder cancer exceeds benefits. Br Med J 1982; 284: 11601.
  • 41
    Thrasher JB, Miller GJ, Wettlaufer JN. Bladder leiomyosarcoma following cyclophosphamide therapy for lupus nephritis. J Urol 1990; 143: 11921.
  • 42
    Thomas E, Brewster DH, Black RJ, Macfarlane GJ. Risk of malignancy among patients with rheumatic conditions. Int J Cancer 2000; 88: 497502.
  • 43
    Rosenthal A, McLaughlin J, Gridley G, Nyren O. Incidence of cancer among patients with systemic sclerosis. Cancer 1995; 76: 9104.
  • 44
    Xu W, Xiang Y, Ruan Z, Zheng W, Cheng J, Dai Q, et al. Menstrual and reproductive factors and endometrial cancer risk: results from a population-based case-control study in urban Shanghai. Int J Cancer 2004; 108: 6139.
  • 45
    Beresford SA, Weiss NS, Voigt LF, McKnight B. Risk of endometrial cancer in relation to use of oestrogen combined with cyclic progestagen therapy in postmenopausal women Lancet 1997; 349: 45861.
  • 46
    Pike MC, Peters RK, Cozen W, Probst-Hensch NM, Felix JC, Wan PC, et al. Estrogen-progestin replacement therapy and endometrial cancer. J Natl Cancer Inst 1997; 89: 11106.
  • 47
    Cooper GS, Dooley MA, Treadwell EL, St Clair EW, Gilkeson GS. Hormonal and reproductive risk factors for development of systemic lupus erythematosus: results of a population-based, case–control study. Arthritis Rheum 2002; 46: 18309.
  • 48
    Takada K, Illei G, Boumpas D. Cyclophosphamide for the treatment of systemic lupus erythematosus. Lupus 2001; 10: 15462.
  • 49
    Mok CC, Lau CS, Ho CT, Lee KW, Mok MY, Wong RW. Safety of hormonal replacement therapy in postmenopausal patients with systemic lupus erythematosus. Scand J Rheumatol 1998; 27: 3426.
  • 50
    Anderson GL, Judd HL, Kaunitz AM, Barad DH, Beresford SA, Pettinger M, et al. Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures: the Women's Health Initiative Randomized Trial. JAMA 2003; 290: 173948.
  • 51
    Chlebowski R, Hendrix S, Langer R, Stefanick M, Gass M, Lane D, et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. JAMA 2003; 289: 324353.
  • 52
    Folsom A, Anderson J, Ross J. Estrogen replacement therapy and ovarian cancer. Epidemiology 2004; 15: 1004.
  • 53
    Rodriguez C, Patel AV, Calle EE, Jacob EJ, Thum MJ. Estrogen replacement therapy and ovarian cancer mortality in a large prospective study of US women. JAMA 2001; 285: 14605.
  • 54
    Bernatsky S, Clarke A, Ramsey-Goldman R, Joseph L, Boivin JF, Rajan R, et al. Hormonal exposures and breast cancer in a sample of women with systemic lupus erythematosus. Rheumatology (Oxford) 2004; 43: 117881.
  • 55
    Nelson RA, Levine AM, Bernstein L. Reproductive factors and risk of intermediate- or high-grade B-cell non-Hodgkin's lymphoma in women. J Clin Oncol 2001; 19: 13817.
  • 56
    Willett E, Smith A, Dovey G, Morgan G, Parker J, Roman E. Tobacco and alcohol consumption and the risk of non-Hodgkin lymphoma. Cancer Causes Control 2004; 15: 77180.